BioSpace News Archive

VolitionRx Limited a multi-national epigenetics company developing simple, easy to use, cost effective blood tests to help diagnose a range of cancers and other diseases in both humans and animals, hosted a capital markets day event yesterday and releases a video of that event.

Poseida Therapeutics, Inc. (NASDAQ:PSTX), and TScan Therapeutics, Inc., a biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies in oncology, today announced a research collaboration and license agreement to explore developing TCR-T cell therapies for the treatment of COVID-19.

Kintara Therapeutics, Inc. (Nasdaq: KTRA) (“Kintara” or the “Company”), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, announced today the execution of an agreement with the Global Coalition for Adaptive Research (GCAR) for VAL-083’s participation in GCAR’s Glioblastoma Adaptive Global Innovative Learning Environment (GBM AGILE) Study.

Biocept, Inc. (Nasdaq: BIOC), a leading commercial provider of molecular diagnostic tests and services, announces the appointment of Samuel D. Riccitelli to its Board of Directors, effective immediately

Scopio Labs, a leading provider of Full Field Morphology (FFM), announced today that it was granted FDA clearance to market and sell its X100 with Full Field Peripheral Blood Smear (Full Field PBS) Application, unlocking the potential of in vitro hematology diagnosis

Researchers at Ben-Gurion University of the Negev (BGU) have developed a novel platform to streamline clinical trials, lower costs, and increase the efficiency and success rate of the drug or medical device development process.

Curis, Inc. highlighted a paper published online in ACS Medicinal Chemistry Letters, a peer-reviewed publication of the American Chemical Society, titled, “Discovery of CA-4948, an Orally Bioavailable IRAK4 Inhibitor for Treatment of Hematologic Malignancies.” The paper describes the preclinical work done to select CA-4948 and its on-target engagement and inhibition of IRAK4 in various animal studies.

Seqirus, a global leader in influenza prevention, today announced new, late-breaking real-world evidence (RWE) to be presented at IDWeek 2020 indicating that an MF59®-adjuvanted trivalent seasonal influenza vaccine (aTIV) was more effective than standard, non-adjuvanted quadrivalent influenza vaccines (IIV4) in reducing influenza-related medical encounters

A Research Collaboration Between LuminUltra, Dalhousie University and Halifax Water Demonstrates Wastewater Data Is a Powerful Tool in Early Detection and Tracking COVID-19 Prevalence within Communities

CryoLife, Inc. (NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today that 2020 third quarter financial results will be released on Wednesday, November 4, 2020 after the market closes.